This article is more than 5 years old. Information may no longer be current.

6 risk factors, treatment advances for Prostate Cancer Awareness Month

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

September is Prostate Cancer Awareness Month, and the Prostate Cancer Foundation is encouraging people to “Step Up For Blue” by raising money for research and sharing stories and experiences.

Prostate cancer is the second most common cancer among men, with over 3 million men living with the disease in the United States, according to the foundation.

In commemoration of the Step Up For Blue campaign, HemOnc Today compiled a list of six updates on risk factors and treatment advances for prostate cancer.

• Conservative management or deferred treatment is the preferred approach for men with low-risk prostate cancer. READ MORE.
• Men who drank at least seven alcoholic drinks per week between ages 15 to 49 years had a more than threefold greater likelihood for developing high-grade prostate cancer than men who did not drink. READ MORE.
• The FDA expanded the approval of enzalutamide (Xtandi; Astellas, Pfizer) — an androgen receptor inhibitor — to include the treatment of nonmetastatic castration-resistant prostate cancer. READ MORE.
• People who ate their evening meal before 9 p.m. or left a 2-hour window between eating dinner and going to bed had a 20% lower risk for breast or prostate cancer than those who ate after 10 p.m. or went to bed fewer than 2 hours after eating. READ MORE.
• Enzalutamide reduced risk for metastasis or death by 71% among men with nonmetastatic castration-resistant prostate cancer and rising PSA levels, according to results of a double-blind phase 3 trial. READ MORE.
• A validated assay for detecting nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified men with prostate cancer who lived longer with taxane chemotherapy than with an androgen receptor signaling inhibitor. READ MORE.